SlideShare ist ein Scribd-Unternehmen logo
1 von 37
Downloaden Sie, um offline zu lesen
DR.Y.SAI KRISHNA
ROAD MAP
 APPROACH TO A CASE OF COPD
 2014 GUIDELINES OF COPD MANAGEMENT
A) Management of Stable COPD
B) Management of COPD exacerbations
 NEWER THERAPIES
Approach
COPD SHOULD BE CONSIDERED
Over the age of 35 to 40
Shortness of breath with chronic cough and sputum
production,
Frequent winter colds
H/O exposure to risk factors for the disease.
STEPS
 Assessment of symptoms
 Assessment of degree of airflow obstruction by spirometry
and other investigations.
 Assessment of risk of exacerbations
 Assessment of comorbidities
Assessment of symptoms
 COPD assessment test ( An 8 item measurement of
health status in COPD)
 Clinical COPD Questionnaire ( Self administered
questionnaire to measure clinical control in patients
with COPD)
 Modified British Medical Reasearch Questionnaire
Assessment of severity (GOLD)
OTHER INVESTIGATIONS
Chest X-ray: Seldom diagnostic but valuable to
exclude alternative diagnoses and establish presence
of significant comorbidities.
Lung Volumes and Diffusing Capacity: Help to
characterize severity, but no role in management.
Oximetry and Arterial Blood Gases: to evaluate
need for supplemental oxygen therapy.
Alpha-1 Antitrypsin Deficiency Screening:
Perform when COPD develops in patients of Caucasian
descent under 45 years or with a strong family history
of COPD.
BODE Index
 APPROXIMATE 4 YEAR SURVIVAL INTERPRETATION
 0-2 Points: 80%
 3-4 Points: 67%
 5-6 Points: 57%
 7-10 Points: 18%
Assessment of risk of exacerbations
To assess risk of exacerbations use history of
exacerbations and spirometry:
 Two or more exacerbations within the last year or an
FEV1 < 50 % of predicted value are indicators of high
risk.
 One or more hospitalizations for COPD exacerbation
should be considered
ABG Measurements(in hospital): PaO2 < 8.0 kPa with or without
PaCO2 > 6.7 kPa when breathing room air indicates respiratory
failure.
Chest radiographs: useful to exclude alternative diagnoses.
ECG: may aid in the diagnosis of coexisting cardiac problems.
Whole blood count: identify polycythemia, anemia or bleeding.
Purulent sputum during an exacerbation: indication to begin
empirical antibiotic treatment.
Biochemical tests: detect electrolyte disturbances, diabetes, and
poor nutrition.
Spirometric tests: not recommended during an exacerbation.
Manage Exacerbations: Assessments
© 2014 Global Initiative for Chronic Obstructive Lung Disease
PATIENT CHARECTERSTIC SPIROMETRIC
CLASSIFICATION
EXACERBATION
PER YEAR
CAT mMRC
A
Low Risk
Less
Symptoms
GOLD 1-2 ≤ 1 < 10 0-1
B
Low Risk
More
Symptoms
GOLD 1-2 ≤ 1 > 10 > 2
C
High Risk
Less
Symptoms
GOLD 3-4 > 2 < 10 0-1
D
High Risk
More
Symptoms
GOLD 3-4 > 2 > 10 > 2
Combined assessment of COPD
Assess COPD Comorbidities
• Cardiovascular diseases
• Osteoporosis
• Respiratory infections
• Anxiety and Depression
• Diabetes
• Lung cancer
• Bronchiectasis
A1 Antitrypsin deficiency
 Alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency, A1AD) is
a genetic disorder that causes defective production of (A1AT), leading
to decreased A1AT activity in the blood and lungs and deposition of
excessive abnormal A1AT protein in liver cells
 Severe A1AT deficiency causes panacinar emphysema or COPD in
adult life in many people with the condition (especially if they are
exposed to cigarette smoke) along with various other conditions such
as
Cirrhosis, Asthma, Wegener’s Granulomatosis, Pancreatitis,
Gallstones, Bronchiectasis, Emphysema, Autoimmune hepatitis,
Cancer
 The serum levels of some of the common genotypes are
 PiMM: 100% (normal)
 PiMS: 80% of normal serum level of A1AT
 PiSS: 60% of normal serum level of A1AT
 PiMZ: 60% of normal serum level of A1AT
 PiSZ: 40% of normal serum level of A1AT
 PiZZ: 10-15% (severe alpha 1-antitrypsin deficiency)
 Treatment
Lung-affected A1AD patients may receive intravenous infusions of
alpha-1 antitrypsin, derived from donated human plasma. This
augmentation therapy is thought to arrest the course of the
disease and halt any further damage to the lungs.
2014
COPD GOLD 2014
GOLD 2014
Managing stable COPD:
Stop smoking
 Encouraging patients with COPD to stop smoking is one
of the most important components of their management
 All COPD patients still smoking, regardless of age,
should be encouraged to stop, and offered help to do so,
at every opportunity
 Record a smoking history, including pack years smoked
 Offer nicotine replacement therapy, varenicline or
bupropion (unless contraindicated) combined with a
support programme to optimise quit rates
Anti smoking therapy
 Nicotine replacement therapy– Transdermal patches,
gums, sprays, lozenges, inhalers
 Bupropion (Zyban) ( Anti depressant)
 Nicotinic receptor partial agonist - Varenicline
(Chantix), Cystisine
 Psychosocial approaches – Cognitive behavioral therapy
VACCINES
Influenza vaccines and Pneumococcal polysaccharide
vaccine is recommended for COPD patients
 65 years or more
 younger than age 65 with FEV1< 40% predicted
Pulmonary rehabitilation
 It is divided into
 Pharmacological
 Non – pharmacological
 Non pharmacological includes exercises, nutritional plan
 Exercise is the cornerstone of pulmonary rehabilitation programs.
Although, exercise training does not directly improves lung function, it
causes improvement in physical condition. There are three basic types
of exercises to be considered. Aerobic exercise tends to improve the
body's ability to use oxygen by decreasing the heart rate and blood
pressure. Strengthening or resistance exercises can help build strength
in the respiratory muscles. Stretching and flexibility exercises like yoga
can enhance breathing coordination.
COPD GOLD 2014
Oxygen: titrate to improve the patient’s hypoxemia with a
target saturation of 88-92%.
Bronchodilators: Short-acting inhaled beta2-agonists with
or without short-acting anticholinergics are preferred.
Systemic Corticosteroids: Shorten recovery time,
improve lung function (FEV1) and arterial hypoxemia (PaO2),
and reduce the risk of early relapse, treatment failure, and
length of hospital stay. A dose of 40 mg prednisone per day for 5
days is recommended .
Manage Exacerbations: Treatment Options
© 2014 Global Initiative for Chronic Obstructive Lung Disease
Alpha-1 antitrypsin augmentation therapy: not
recommended for patients with COPD that is unrelated to the
genetic deficiency.
Mucolytics: Patients with viscous sputum may benefit from
mucolytics; overall benefits are very small.
Antitussives: Not recommended.
Vasodilators: Nitric oxide is contraindicated in stable COPD. The
use of endothelium-modulating agents for the treatment of
pulmonary hypertension associated with COPD is not
recommended.
Therapeutic Options: Other
Pharmacologic Treatments
© 2014 Global Initiative for Chronic Obstructive Lung Disease
 The phospodiesterase-4 inhibitor Roflumilast may be useful to
reduce exacerbations for patients with FEV1 < 50% of predicted,
chronic bronchitis, and frequent exacerbations
 Theophylline –
Theophylline is less effective and less well tolerated than inhaled
long- acting bronchodilators and is not recommended if those
drugs are available and affordable.
There is evidence for a modest bronchodilator effect and some
symptomatic benefit in stable COPD. Addition of theophylline
to salmeterol produces a greater increase in FEV1 and a
decrease in breathlessness than salmeterol alone.
Low dose theophylline reduces exacerbations but does not
improve post-bronchodilator lung function.
Role of Antibiotics
 Antibiotics should be given to patients with 3 cardinal
symptoms
 A) Increased Dyspnoea
 B) Increased sputum volume
 C) Increased sputum prevalence
 And people who are on mechanical ventilation
assistance
NEJM Aug 25th 2011
 Adding Azithromycin, at a dose of 250 mg daily, for 1 year to
the usual treatment of patients who have an increased risk of
acute exacerbations of COPD
 Advantages
 1) Decreased the number of exacerbations per year
 2) the incidence of colonization with selected respiratory
pathogens
 3) Increased the quality of life
 Disadvantages
 1) Increased hearing loss in a small % of patients
 2) Prolonged QTc
Oxygen Therapy: The long-term administration of
oxygen (> 15 hours per day) to patients with chronic
respiratory failure has been shown to increase
survival in patients with severe, resting hypoxemia.
Ventilatory Support: Combination of noninvasive
ventilation (NIV) with long-term oxygen therapy may
be of some use in a selected subset of patients,
particularly in those with pronounced daytime
hypercapnia.
Therapeutic Options: Other Treatments
© 2014 Global Initiative for Chronic Obstructive Lung Disease
COPD GOLD 2014
Advantages Of NIPPV
 Decreases need for invasive ventilation and may be
associated with improved outcome.
 CPAP alone can reduce work of breathing in COPD during
weaning and during sleep.
 BiPAP weaning may be better than weaning on pressure
support via an ETT.
 A lower rate of treatment failure ;lower mortality rate.
 Greater improvements in the 1-hour
post-treatment pH and PaCO2 levels
Indication and Relative contraindication for NIPPV
 Selection Criteria:
 Moderate to severe dyspnea with the use of accessory muscles,
paradoxical breathing.
 Moderate to severe acidosis PH  7.35 and/or PaCO2 > 45
mmHg
or PaO2/FiO2 < 200
 RR > 25 breaths/min,accessory muscle
 Exclusion Criteria:
 Respiratory arrest. Cardiovascular instability.
 Burns Extreme obesity.
 Craniofacial trauma. APACHE score >29
 High aspiration risk(. Cannot protect the airway )
Indications of IIPPV:
 Hypoxemia that has not corrected with NIPPV
 Exclusion criteria of NIPPV
 Sever acidosis PH<7.25 and/or PaCO2 >60 mmHg
 Impending respiratory arrest
 Respiratory rate > 36 breaths/minute
 Use of all accessory muscles
 Thoracoabdominal paradox
 Even minor mental state changes
 Patient's subjective sense of exhaustion
 Cardiovascular instability
Management of a COPD patient on ventilator
 Use low tidal volumes to prevent stretching of the lung
parenchyma and VIL (Ventilator induced injury)
 Another adverse effect of invasive mechanical ventilation in
COPD is the generation or aggravation of PEEPi
 Auto (intrinsic) PEEP — Incomplete expiration prior to the initiation
of the next breath causes progressive air trapping . This
accumulation of air increases alveolar pressure at the end of
expiration, which is referred to as auto-PEEP.
 Auto-PEEP develops commonly in high minute ventilation expiratory
flow limitation (obstructed airway) and expiratory resistance
(narrow airway).
 Once auto-PEEP is identified, steps should be taken to stop or
reduce the pressure build-up. When auto-PEEP persists despite
management of its underlying cause, applied PEEP may be helpful if
the patient has an expiratory flow limitation (obstruction).
 Applied (extrinsic) PEEP —
 A small amount of applied PEEP (3 to 5 cmH2O) is used in most
mechanically ventilated patients to mitigate end-expiratory
alveolar collapse. A higher level of applied PEEP (>5 cmH2O) is
sometimes used to improve hypoxemia or reduce VILI in
patients with acute lung injury, acute respiratory distress
syndrome, or other types of hypoxemic respiratory failure.
 Complications
 Decrease in systemic venous return
 Pulmonary baotrauma can be caused. Pulmonary barotrauma is
lung injury that results from the hyperinflation of alveoli past
the rupture point.
 Raised ICP
 Renal functions and electrolyte imbalances, due to decreased
venous return metabolism of certain drugs are altered and acid-
base balance is impeded
COPD GOLD 2014
Lung volume reduction surgery (LVRS) is more
efficacious than medical therapy among patients
with upper-lobe predominant emphysema and low
exercise capacity.
LVRS is costly relative to health-care programs not
including surgery.
In appropriately selected patients with very severe
COPD, lung transplantation has been shown to
improve quality of life and functional capacity.
Surgical Treatments
© 2014 Global Initiative for Chronic Obstructive Lung Disease
LVRS Lung Transplantation
 Patient Factors Favoring LVRS over
Lung Transplantation
 • Age > 65 yr
 • Chronic medical conditions: Chronic
active viral hepatitis B, hepatitis C with
biopsy-proven histologic evidence of liver
disease, or HIV infection
 • Organ system dysfunction precluding
appropriate immunosuppressive therapy:
renal insufficiency, liver dysfunction,
neuropathy, significant osteoporosis,
uncontrolled diabetes
 • Refractory gastroesophageal reflux
disease
 • Malignancy
 • Inability to maintain long-term follow-up
 • Psychiatric conditions
 • Lack of social support
 Patient Factors Favoring Lung
Transplantation over LVRS
 • FEV1 ⩽ 20% predicted and either
homogeneous disease or DlCO ⩽
20% predicted
 • Lack of emphysema on HRCT
 • TLC < 100% predicted
 • RV < 150% predicted
 • PaCO2 > 60 mm Hg
 • PaO2 < 45 mm Hg
 • 6MWD ⩽ 140 m, < 3 min
unloaded pedaling on cycle
ergometer
 • Pulmonary hypertension
 • Clinically significant
bronchiectasis and/or recurrent
pulmonary infections
Newer modalities
 A new study called the STASCOPE study funded by the National Heart
Lung and Blood Institute is being conducted to determine if
Simvastatin might reduce swelling in the lungs in patients with
COPD.
 If it is found that Simvastatin reduces lung inflammation, there is a
possibility that the statin drug could also the limit the number or
severity of the exacerbations.
 Beta Blockers may reduce mortality and exacerbations when added
to established inhaled stepwise therapy for COPD, independently of
CVD and cardiac drugs, and without adverse effects on pulmonary
function.
Asthma COPD Overlap Syndrome (ACOS)
 A chapter on Asthma and COPD Overlap Syndrome (ACOS)
is in preparation by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD).
 major criteria for ACOS:
 a physician diagnosis of asthma and COPD in the same
patient,
 history or evidence of atopy, for example, hay fever, elevated
total IgE,
 age 40 years or more,
 smoking >10 pack-years, postbronchodilator FEV1 <80%
predicted and FEV1/FVC <70%.
 A ≥15% increase in FEV1 or ≥12% and ≥200 ml increase in
FEV1 postbronchodilator treatment with albuterol would be
a minor criteria

Weitere ähnliche Inhalte

Was ist angesagt?

COPD definition, phenotypes, epidemiology
COPD definition, phenotypes, epidemiologyCOPD definition, phenotypes, epidemiology
COPD definition, phenotypes, epidemiologySURABHI SUSHMA REDDY
 
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)Sarfraz Saleemi
 
Diagnosis of COPD
Diagnosis of COPDDiagnosis of COPD
Diagnosis of COPDGamal Agmy
 
Copd(chronic obstructive pulmonary disease)
Copd(chronic obstructive pulmonary disease)Copd(chronic obstructive pulmonary disease)
Copd(chronic obstructive pulmonary disease)Likhila Abraham
 
Systemic Manifestations of COPD
Systemic Manifestations of COPDSystemic Manifestations of COPD
Systemic Manifestations of COPDAshraf ElAdawy
 
Att induced hepatitis.pptx new
Att induced hepatitis.pptx newAtt induced hepatitis.pptx new
Att induced hepatitis.pptx newBhargav Kiran
 
Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Rahil Dalal
 
Interstitial Lung Diseases [ILD] Approach to Management
Interstitial Lung Diseases [ILD] Approach to ManagementInterstitial Lung Diseases [ILD] Approach to Management
Interstitial Lung Diseases [ILD] Approach to ManagementArun Vasireddy
 
Management of tb in ckd dr Tareq tantawy
Management of tb in ckd dr Tareq tantawyManagement of tb in ckd dr Tareq tantawy
Management of tb in ckd dr Tareq tantawyFarragBahbah
 
Adjunctive corticosteroid therapy in tuberculosis management
Adjunctive corticosteroid therapy in tuberculosis managementAdjunctive corticosteroid therapy in tuberculosis management
Adjunctive corticosteroid therapy in tuberculosis managementMohit Aggarwal
 
Acute exacerbation of COPD
Acute exacerbation of COPDAcute exacerbation of COPD
Acute exacerbation of COPDThomas Kurian
 
Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.Hiba Ashibany
 
ATT induced liver injury
ATT induced liver injuryATT induced liver injury
ATT induced liver injuryikramdr01
 

Was ist angesagt? (20)

COPD definition, phenotypes, epidemiology
COPD definition, phenotypes, epidemiologyCOPD definition, phenotypes, epidemiology
COPD definition, phenotypes, epidemiology
 
Copd
CopdCopd
Copd
 
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
 
Diagnosis of COPD
Diagnosis of COPDDiagnosis of COPD
Diagnosis of COPD
 
Copd(chronic obstructive pulmonary disease)
Copd(chronic obstructive pulmonary disease)Copd(chronic obstructive pulmonary disease)
Copd(chronic obstructive pulmonary disease)
 
NON RESOLVING PNEUMONIA
NON RESOLVING PNEUMONIANON RESOLVING PNEUMONIA
NON RESOLVING PNEUMONIA
 
COPD ppt
COPD pptCOPD ppt
COPD ppt
 
Systemic Manifestations of COPD
Systemic Manifestations of COPDSystemic Manifestations of COPD
Systemic Manifestations of COPD
 
Copd exacerbation
Copd exacerbationCopd exacerbation
Copd exacerbation
 
Att induced hepatitis.pptx new
Att induced hepatitis.pptx newAtt induced hepatitis.pptx new
Att induced hepatitis.pptx new
 
Copd update 2015
Copd update 2015Copd update 2015
Copd update 2015
 
Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)
 
COPD
COPDCOPD
COPD
 
Interstitial Lung Diseases [ILD] Approach to Management
Interstitial Lung Diseases [ILD] Approach to ManagementInterstitial Lung Diseases [ILD] Approach to Management
Interstitial Lung Diseases [ILD] Approach to Management
 
Management of tb in ckd dr Tareq tantawy
Management of tb in ckd dr Tareq tantawyManagement of tb in ckd dr Tareq tantawy
Management of tb in ckd dr Tareq tantawy
 
COPD
COPD COPD
COPD
 
Adjunctive corticosteroid therapy in tuberculosis management
Adjunctive corticosteroid therapy in tuberculosis managementAdjunctive corticosteroid therapy in tuberculosis management
Adjunctive corticosteroid therapy in tuberculosis management
 
Acute exacerbation of COPD
Acute exacerbation of COPDAcute exacerbation of COPD
Acute exacerbation of COPD
 
Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.
 
ATT induced liver injury
ATT induced liver injuryATT induced liver injury
ATT induced liver injury
 

Andere mochten auch

COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
COPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslamCOPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslamDr.Aslam calicut
 
Chronic obstructive pulmonary disease (copd) power point
Chronic obstructive pulmonary disease (copd) power pointChronic obstructive pulmonary disease (copd) power point
Chronic obstructive pulmonary disease (copd) power pointwandatardy
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASECHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASETomcy Thankachan
 
COPD (Chronic Obstructive Pulmonary Disease)
COPD (Chronic Obstructive Pulmonary Disease)COPD (Chronic Obstructive Pulmonary Disease)
COPD (Chronic Obstructive Pulmonary Disease)HoneymoonSwami.com
 
COPD.ppt
COPD.pptCOPD.ppt
COPD.pptShama
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseimangalal
 
COPD new drugs new devices
COPD new drugs new devicesCOPD new drugs new devices
COPD new drugs new devicesAshraf ElAdawy
 
COPD case presentation by Amnah AlLail
COPD case presentation by Amnah AlLail COPD case presentation by Amnah AlLail
COPD case presentation by Amnah AlLail Maher AlQuaimi
 
COPD case presentation
COPD case presentation COPD case presentation
COPD case presentation sara_abudahab
 
Case study patient with copd
Case study patient with copdCase study patient with copd
Case study patient with copdnawal al-matary
 
Gold - global initiative against COPD
Gold - global initiative against COPDGold - global initiative against COPD
Gold - global initiative against COPDadithya2115
 
Asthma Presentation
Asthma PresentationAsthma Presentation
Asthma Presentationkerri035
 
Copd lecture notes
Copd lecture notesCopd lecture notes
Copd lecture noteshomebwoi
 
Case presentation
Case presentationCase presentation
Case presentationSyed Hafiz
 

Andere mochten auch (20)

COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
COPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslamCOPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
 
Chronic obstructive pulmonary disease (copd) power point
Chronic obstructive pulmonary disease (copd) power pointChronic obstructive pulmonary disease (copd) power point
Chronic obstructive pulmonary disease (copd) power point
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASECHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
 
COPD (Chronic Obstructive Pulmonary Disease)
COPD (Chronic Obstructive Pulmonary Disease)COPD (Chronic Obstructive Pulmonary Disease)
COPD (Chronic Obstructive Pulmonary Disease)
 
COPD.ppt
COPD.pptCOPD.ppt
COPD.ppt
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
 
COPD
COPDCOPD
COPD
 
COPD new drugs new devices
COPD new drugs new devicesCOPD new drugs new devices
COPD new drugs new devices
 
COPD case presentation by Amnah AlLail
COPD case presentation by Amnah AlLail COPD case presentation by Amnah AlLail
COPD case presentation by Amnah AlLail
 
Copd 2017
Copd 2017  Copd 2017
Copd 2017
 
Pathology of COPD
Pathology of COPDPathology of COPD
Pathology of COPD
 
COPD case presentation
COPD case presentation COPD case presentation
COPD case presentation
 
Case study patient with copd
Case study patient with copdCase study patient with copd
Case study patient with copd
 
Copd Management
Copd ManagementCopd Management
Copd Management
 
Gold - global initiative against COPD
Gold - global initiative against COPDGold - global initiative against COPD
Gold - global initiative against COPD
 
Asthma Presentation
Asthma PresentationAsthma Presentation
Asthma Presentation
 
Copd lecture notes
Copd lecture notesCopd lecture notes
Copd lecture notes
 
Copd management
Copd managementCopd management
Copd management
 
COPD
COPDCOPD
COPD
 
Case presentation
Case presentationCase presentation
Case presentation
 

Ähnlich wie COPD GOLD 2014

Pulmonary Arterial Hypetension.pptx
Pulmonary Arterial Hypetension.pptxPulmonary Arterial Hypetension.pptx
Pulmonary Arterial Hypetension.pptxNannikaPradhan
 
Asthma-COPD Overlap Syndrome - ACOS
Asthma-COPD Overlap Syndrome - ACOSAsthma-COPD Overlap Syndrome - ACOS
Asthma-COPD Overlap Syndrome - ACOSNino JN Doydora
 
Critical care treatment guidelines Govt of India
Critical care treatment guidelines Govt of India Critical care treatment guidelines Govt of India
Critical care treatment guidelines Govt of India Dr Jitu Lal Meena
 
Gold pocket 2015_feb18
Gold pocket 2015_feb18Gold pocket 2015_feb18
Gold pocket 2015_feb18Vũ Nhân
 
Gold pocket 2015_feb18
Gold pocket 2015_feb18Gold pocket 2015_feb18
Gold pocket 2015_feb18FJ QB
 
Chronic obstructive airway disease (coad)
Chronic obstructive airway disease (coad)Chronic obstructive airway disease (coad)
Chronic obstructive airway disease (coad)Nandinii Ramasenderan
 
Primary care talk NICE 2011
Primary care talk NICE 2011Primary care talk NICE 2011
Primary care talk NICE 2011copdeducation
 
GOLD16 – MANAGEMENT AND TREATMENT OF COPD
GOLD16 – MANAGEMENT AND TREATMENT OF COPDGOLD16 – MANAGEMENT AND TREATMENT OF COPD
GOLD16 – MANAGEMENT AND TREATMENT OF COPDevidenciaterapeutica.com
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseRanjita Pallavi
 
Role of Inhaled Corticosteroids in COPD
Role of Inhaled Corticosteroids  in COPDRole of Inhaled Corticosteroids  in COPD
Role of Inhaled Corticosteroids in COPDGamal Agmy
 
Pharmacological Management of COPD
Pharmacological Management of COPD  Pharmacological Management of COPD
Pharmacological Management of COPD Ashraf ElAdawy
 

Ähnlich wie COPD GOLD 2014 (20)

COPD 1.pptx
COPD 1.pptxCOPD 1.pptx
COPD 1.pptx
 
COPD 2014
COPD 2014COPD 2014
COPD 2014
 
The Gold 2003 Update
The Gold 2003 UpdateThe Gold 2003 Update
The Gold 2003 Update
 
COPD - Ldh Jan 2010.ppt
COPD - Ldh Jan 2010.pptCOPD - Ldh Jan 2010.ppt
COPD - Ldh Jan 2010.ppt
 
Pulmonary Arterial Hypetension.pptx
Pulmonary Arterial Hypetension.pptxPulmonary Arterial Hypetension.pptx
Pulmonary Arterial Hypetension.pptx
 
Ers Ats Copd Guidelines
Ers Ats Copd GuidelinesErs Ats Copd Guidelines
Ers Ats Copd Guidelines
 
Copd 2006
Copd 2006Copd 2006
Copd 2006
 
BA vs COPD.pptx
BA vs COPD.pptxBA vs COPD.pptx
BA vs COPD.pptx
 
Epoc
EpocEpoc
Epoc
 
Asthma-COPD Overlap Syndrome - ACOS
Asthma-COPD Overlap Syndrome - ACOSAsthma-COPD Overlap Syndrome - ACOS
Asthma-COPD Overlap Syndrome - ACOS
 
Critical care treatment guidelines Govt of India
Critical care treatment guidelines Govt of India Critical care treatment guidelines Govt of India
Critical care treatment guidelines Govt of India
 
Gold pocket 2015_feb18
Gold pocket 2015_feb18Gold pocket 2015_feb18
Gold pocket 2015_feb18
 
Gold pocket 2015_feb18
Gold pocket 2015_feb18Gold pocket 2015_feb18
Gold pocket 2015_feb18
 
Chronic obstructive airway disease (coad)
Chronic obstructive airway disease (coad)Chronic obstructive airway disease (coad)
Chronic obstructive airway disease (coad)
 
Primary care talk NICE 2011
Primary care talk NICE 2011Primary care talk NICE 2011
Primary care talk NICE 2011
 
GOLD16 – MANAGEMENT AND TREATMENT OF COPD
GOLD16 – MANAGEMENT AND TREATMENT OF COPDGOLD16 – MANAGEMENT AND TREATMENT OF COPD
GOLD16 – MANAGEMENT AND TREATMENT OF COPD
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
 
stable COPD.pptx
stable COPD.pptxstable COPD.pptx
stable COPD.pptx
 
Role of Inhaled Corticosteroids in COPD
Role of Inhaled Corticosteroids  in COPDRole of Inhaled Corticosteroids  in COPD
Role of Inhaled Corticosteroids in COPD
 
Pharmacological Management of COPD
Pharmacological Management of COPD  Pharmacological Management of COPD
Pharmacological Management of COPD
 

Kürzlich hochgeladen

Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 

Kürzlich hochgeladen (20)

Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 

COPD GOLD 2014

  • 2. ROAD MAP  APPROACH TO A CASE OF COPD  2014 GUIDELINES OF COPD MANAGEMENT A) Management of Stable COPD B) Management of COPD exacerbations  NEWER THERAPIES
  • 3. Approach COPD SHOULD BE CONSIDERED Over the age of 35 to 40 Shortness of breath with chronic cough and sputum production, Frequent winter colds H/O exposure to risk factors for the disease. STEPS  Assessment of symptoms  Assessment of degree of airflow obstruction by spirometry and other investigations.  Assessment of risk of exacerbations  Assessment of comorbidities
  • 4. Assessment of symptoms  COPD assessment test ( An 8 item measurement of health status in COPD)  Clinical COPD Questionnaire ( Self administered questionnaire to measure clinical control in patients with COPD)  Modified British Medical Reasearch Questionnaire
  • 6. OTHER INVESTIGATIONS Chest X-ray: Seldom diagnostic but valuable to exclude alternative diagnoses and establish presence of significant comorbidities. Lung Volumes and Diffusing Capacity: Help to characterize severity, but no role in management. Oximetry and Arterial Blood Gases: to evaluate need for supplemental oxygen therapy. Alpha-1 Antitrypsin Deficiency Screening: Perform when COPD develops in patients of Caucasian descent under 45 years or with a strong family history of COPD.
  • 7. BODE Index  APPROXIMATE 4 YEAR SURVIVAL INTERPRETATION  0-2 Points: 80%  3-4 Points: 67%  5-6 Points: 57%  7-10 Points: 18%
  • 8. Assessment of risk of exacerbations To assess risk of exacerbations use history of exacerbations and spirometry:  Two or more exacerbations within the last year or an FEV1 < 50 % of predicted value are indicators of high risk.  One or more hospitalizations for COPD exacerbation should be considered
  • 9. ABG Measurements(in hospital): PaO2 < 8.0 kPa with or without PaCO2 > 6.7 kPa when breathing room air indicates respiratory failure. Chest radiographs: useful to exclude alternative diagnoses. ECG: may aid in the diagnosis of coexisting cardiac problems. Whole blood count: identify polycythemia, anemia or bleeding. Purulent sputum during an exacerbation: indication to begin empirical antibiotic treatment. Biochemical tests: detect electrolyte disturbances, diabetes, and poor nutrition. Spirometric tests: not recommended during an exacerbation. Manage Exacerbations: Assessments © 2014 Global Initiative for Chronic Obstructive Lung Disease
  • 10. PATIENT CHARECTERSTIC SPIROMETRIC CLASSIFICATION EXACERBATION PER YEAR CAT mMRC A Low Risk Less Symptoms GOLD 1-2 ≤ 1 < 10 0-1 B Low Risk More Symptoms GOLD 1-2 ≤ 1 > 10 > 2 C High Risk Less Symptoms GOLD 3-4 > 2 < 10 0-1 D High Risk More Symptoms GOLD 3-4 > 2 > 10 > 2 Combined assessment of COPD
  • 11. Assess COPD Comorbidities • Cardiovascular diseases • Osteoporosis • Respiratory infections • Anxiety and Depression • Diabetes • Lung cancer • Bronchiectasis
  • 12. A1 Antitrypsin deficiency  Alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency, A1AD) is a genetic disorder that causes defective production of (A1AT), leading to decreased A1AT activity in the blood and lungs and deposition of excessive abnormal A1AT protein in liver cells  Severe A1AT deficiency causes panacinar emphysema or COPD in adult life in many people with the condition (especially if they are exposed to cigarette smoke) along with various other conditions such as Cirrhosis, Asthma, Wegener’s Granulomatosis, Pancreatitis, Gallstones, Bronchiectasis, Emphysema, Autoimmune hepatitis, Cancer
  • 13.  The serum levels of some of the common genotypes are  PiMM: 100% (normal)  PiMS: 80% of normal serum level of A1AT  PiSS: 60% of normal serum level of A1AT  PiMZ: 60% of normal serum level of A1AT  PiSZ: 40% of normal serum level of A1AT  PiZZ: 10-15% (severe alpha 1-antitrypsin deficiency)  Treatment Lung-affected A1AD patients may receive intravenous infusions of alpha-1 antitrypsin, derived from donated human plasma. This augmentation therapy is thought to arrest the course of the disease and halt any further damage to the lungs.
  • 14. 2014
  • 17. Managing stable COPD: Stop smoking  Encouraging patients with COPD to stop smoking is one of the most important components of their management  All COPD patients still smoking, regardless of age, should be encouraged to stop, and offered help to do so, at every opportunity  Record a smoking history, including pack years smoked  Offer nicotine replacement therapy, varenicline or bupropion (unless contraindicated) combined with a support programme to optimise quit rates
  • 18. Anti smoking therapy  Nicotine replacement therapy– Transdermal patches, gums, sprays, lozenges, inhalers  Bupropion (Zyban) ( Anti depressant)  Nicotinic receptor partial agonist - Varenicline (Chantix), Cystisine  Psychosocial approaches – Cognitive behavioral therapy VACCINES Influenza vaccines and Pneumococcal polysaccharide vaccine is recommended for COPD patients  65 years or more  younger than age 65 with FEV1< 40% predicted
  • 19. Pulmonary rehabitilation  It is divided into  Pharmacological  Non – pharmacological  Non pharmacological includes exercises, nutritional plan  Exercise is the cornerstone of pulmonary rehabilitation programs. Although, exercise training does not directly improves lung function, it causes improvement in physical condition. There are three basic types of exercises to be considered. Aerobic exercise tends to improve the body's ability to use oxygen by decreasing the heart rate and blood pressure. Strengthening or resistance exercises can help build strength in the respiratory muscles. Stretching and flexibility exercises like yoga can enhance breathing coordination.
  • 21. Oxygen: titrate to improve the patient’s hypoxemia with a target saturation of 88-92%. Bronchodilators: Short-acting inhaled beta2-agonists with or without short-acting anticholinergics are preferred. Systemic Corticosteroids: Shorten recovery time, improve lung function (FEV1) and arterial hypoxemia (PaO2), and reduce the risk of early relapse, treatment failure, and length of hospital stay. A dose of 40 mg prednisone per day for 5 days is recommended . Manage Exacerbations: Treatment Options © 2014 Global Initiative for Chronic Obstructive Lung Disease
  • 22. Alpha-1 antitrypsin augmentation therapy: not recommended for patients with COPD that is unrelated to the genetic deficiency. Mucolytics: Patients with viscous sputum may benefit from mucolytics; overall benefits are very small. Antitussives: Not recommended. Vasodilators: Nitric oxide is contraindicated in stable COPD. The use of endothelium-modulating agents for the treatment of pulmonary hypertension associated with COPD is not recommended. Therapeutic Options: Other Pharmacologic Treatments © 2014 Global Initiative for Chronic Obstructive Lung Disease
  • 23.  The phospodiesterase-4 inhibitor Roflumilast may be useful to reduce exacerbations for patients with FEV1 < 50% of predicted, chronic bronchitis, and frequent exacerbations  Theophylline – Theophylline is less effective and less well tolerated than inhaled long- acting bronchodilators and is not recommended if those drugs are available and affordable. There is evidence for a modest bronchodilator effect and some symptomatic benefit in stable COPD. Addition of theophylline to salmeterol produces a greater increase in FEV1 and a decrease in breathlessness than salmeterol alone. Low dose theophylline reduces exacerbations but does not improve post-bronchodilator lung function.
  • 24. Role of Antibiotics  Antibiotics should be given to patients with 3 cardinal symptoms  A) Increased Dyspnoea  B) Increased sputum volume  C) Increased sputum prevalence  And people who are on mechanical ventilation assistance
  • 25. NEJM Aug 25th 2011  Adding Azithromycin, at a dose of 250 mg daily, for 1 year to the usual treatment of patients who have an increased risk of acute exacerbations of COPD  Advantages  1) Decreased the number of exacerbations per year  2) the incidence of colonization with selected respiratory pathogens  3) Increased the quality of life  Disadvantages  1) Increased hearing loss in a small % of patients  2) Prolonged QTc
  • 26. Oxygen Therapy: The long-term administration of oxygen (> 15 hours per day) to patients with chronic respiratory failure has been shown to increase survival in patients with severe, resting hypoxemia. Ventilatory Support: Combination of noninvasive ventilation (NIV) with long-term oxygen therapy may be of some use in a selected subset of patients, particularly in those with pronounced daytime hypercapnia. Therapeutic Options: Other Treatments © 2014 Global Initiative for Chronic Obstructive Lung Disease
  • 28. Advantages Of NIPPV  Decreases need for invasive ventilation and may be associated with improved outcome.  CPAP alone can reduce work of breathing in COPD during weaning and during sleep.  BiPAP weaning may be better than weaning on pressure support via an ETT.  A lower rate of treatment failure ;lower mortality rate.  Greater improvements in the 1-hour post-treatment pH and PaCO2 levels
  • 29. Indication and Relative contraindication for NIPPV  Selection Criteria:  Moderate to severe dyspnea with the use of accessory muscles, paradoxical breathing.  Moderate to severe acidosis PH  7.35 and/or PaCO2 > 45 mmHg or PaO2/FiO2 < 200  RR > 25 breaths/min,accessory muscle  Exclusion Criteria:  Respiratory arrest. Cardiovascular instability.  Burns Extreme obesity.  Craniofacial trauma. APACHE score >29  High aspiration risk(. Cannot protect the airway )
  • 30. Indications of IIPPV:  Hypoxemia that has not corrected with NIPPV  Exclusion criteria of NIPPV  Sever acidosis PH<7.25 and/or PaCO2 >60 mmHg  Impending respiratory arrest  Respiratory rate > 36 breaths/minute  Use of all accessory muscles  Thoracoabdominal paradox  Even minor mental state changes  Patient's subjective sense of exhaustion  Cardiovascular instability
  • 31. Management of a COPD patient on ventilator  Use low tidal volumes to prevent stretching of the lung parenchyma and VIL (Ventilator induced injury)  Another adverse effect of invasive mechanical ventilation in COPD is the generation or aggravation of PEEPi  Auto (intrinsic) PEEP — Incomplete expiration prior to the initiation of the next breath causes progressive air trapping . This accumulation of air increases alveolar pressure at the end of expiration, which is referred to as auto-PEEP.  Auto-PEEP develops commonly in high minute ventilation expiratory flow limitation (obstructed airway) and expiratory resistance (narrow airway).  Once auto-PEEP is identified, steps should be taken to stop or reduce the pressure build-up. When auto-PEEP persists despite management of its underlying cause, applied PEEP may be helpful if the patient has an expiratory flow limitation (obstruction).
  • 32.  Applied (extrinsic) PEEP —  A small amount of applied PEEP (3 to 5 cmH2O) is used in most mechanically ventilated patients to mitigate end-expiratory alveolar collapse. A higher level of applied PEEP (>5 cmH2O) is sometimes used to improve hypoxemia or reduce VILI in patients with acute lung injury, acute respiratory distress syndrome, or other types of hypoxemic respiratory failure.  Complications  Decrease in systemic venous return  Pulmonary baotrauma can be caused. Pulmonary barotrauma is lung injury that results from the hyperinflation of alveoli past the rupture point.  Raised ICP  Renal functions and electrolyte imbalances, due to decreased venous return metabolism of certain drugs are altered and acid- base balance is impeded
  • 34. Lung volume reduction surgery (LVRS) is more efficacious than medical therapy among patients with upper-lobe predominant emphysema and low exercise capacity. LVRS is costly relative to health-care programs not including surgery. In appropriately selected patients with very severe COPD, lung transplantation has been shown to improve quality of life and functional capacity. Surgical Treatments © 2014 Global Initiative for Chronic Obstructive Lung Disease
  • 35. LVRS Lung Transplantation  Patient Factors Favoring LVRS over Lung Transplantation  • Age > 65 yr  • Chronic medical conditions: Chronic active viral hepatitis B, hepatitis C with biopsy-proven histologic evidence of liver disease, or HIV infection  • Organ system dysfunction precluding appropriate immunosuppressive therapy: renal insufficiency, liver dysfunction, neuropathy, significant osteoporosis, uncontrolled diabetes  • Refractory gastroesophageal reflux disease  • Malignancy  • Inability to maintain long-term follow-up  • Psychiatric conditions  • Lack of social support  Patient Factors Favoring Lung Transplantation over LVRS  • FEV1 ⩽ 20% predicted and either homogeneous disease or DlCO ⩽ 20% predicted  • Lack of emphysema on HRCT  • TLC < 100% predicted  • RV < 150% predicted  • PaCO2 > 60 mm Hg  • PaO2 < 45 mm Hg  • 6MWD ⩽ 140 m, < 3 min unloaded pedaling on cycle ergometer  • Pulmonary hypertension  • Clinically significant bronchiectasis and/or recurrent pulmonary infections
  • 36. Newer modalities  A new study called the STASCOPE study funded by the National Heart Lung and Blood Institute is being conducted to determine if Simvastatin might reduce swelling in the lungs in patients with COPD.  If it is found that Simvastatin reduces lung inflammation, there is a possibility that the statin drug could also the limit the number or severity of the exacerbations.  Beta Blockers may reduce mortality and exacerbations when added to established inhaled stepwise therapy for COPD, independently of CVD and cardiac drugs, and without adverse effects on pulmonary function.
  • 37. Asthma COPD Overlap Syndrome (ACOS)  A chapter on Asthma and COPD Overlap Syndrome (ACOS) is in preparation by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).  major criteria for ACOS:  a physician diagnosis of asthma and COPD in the same patient,  history or evidence of atopy, for example, hay fever, elevated total IgE,  age 40 years or more,  smoking >10 pack-years, postbronchodilator FEV1 <80% predicted and FEV1/FVC <70%.  A ≥15% increase in FEV1 or ≥12% and ≥200 ml increase in FEV1 postbronchodilator treatment with albuterol would be a minor criteria